Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding: Mechanistic Insights and Research Implications

Study Background and Research Question

The renin–angiotensin–aldosterone system (RAAS) is central to cardiovascular and renal regulation, with angiotensin peptides such as angiotensin II (1–8) and its shorter derivatives playing established roles in blood pressure control, aldosterone secretion, and tissue remodeling. With the emergence of SARS-CoV-2, attention has turned to RAAS peptides because the virus exploits ACE2, a key RAAS enzyme, as its primary entry receptor. Recent evidence suggests that alternative host receptors, notably AXL, can mediate spike protein binding and viral entry, particularly in cells with low ACE2 expression. This raises a pivotal question: Do endogenous angiotensin peptides modulate the interaction between SARS-CoV-2 spike protein and its host receptors, especially AXL, thereby influencing viral infectivity and disease progression?

Key Innovation from the Reference Study

The study by Oliveira et al. (2025) provides the first systematic analysis of how various naturally occurring angiotensin peptides modulate binding between the SARS-CoV-2 spike protein and its host cell receptors. The key finding is that certain angiotensin peptides, especially those generated by N-terminal truncation (such as Angiotensin III and IV), markedly enhance spike–AXL binding, sometimes with even greater potency than angiotensin II itself (source: paper). This work extends the functional repertoire of RAAS peptides beyond cardiovascular regulation, implicating them in viral pathogenesis mechanisms.

Methods and Experimental Design Insights

Oliveira et al. employed antibody-based binding assays to quantify the interaction between purified SARS-CoV-2 spike protein and three key receptors: ACE2, neuropilin-1 (NRP1), and AXL. By systematically adding different angiotensin peptides—including angiotensin I, II, III (Arg-Val-Tyr-Ile-His-Pro-Phe), IV, and further truncated variants—the authors assessed the degree to which each peptide modulates spike–receptor binding. Peptide modifications, such as tyrosine substitution or phosphorylation, were also tested to determine structure–activity relationships. The experimental setup allowed direct comparison of binding enhancements across a panel of physiologically relevant angiotensin derivatives (source: paper).

Core Findings and Why They Matter

Several crucial observations emerged from this work:

• Angiotensin II increases spike–AXL binding two-fold, with no significant effect on ACE2 or NRP1 binding. In contrast, angiotensin I (the longer decapeptide) showed no effect, highlighting the importance of peptide truncation (source: paper).
• N-terminally truncated peptides, including Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe) and Angiotensin IV, further enhance spike–AXL binding capacity. Notably, Angiotensin IV yielded a 2.7-fold increase, surpassing the effect of Angiotensin II (source: paper).
• Structure–activity relationships reveal that tyrosine at position 4 is a critical determinant: substitution or phosphorylation of this residue boosts spike–AXL binding, suggesting a direct role for peptide sequence and modification in modulating receptor interactions (source: paper).
• Among the peptides tested, only the shortest C-terminal derivatives (e.g., Angiotensin (1–6), (1–7)) achieved enhancement similar to Angiotensin II, while N-terminal deletions, such as Angiotensin III, consistently produced stronger effects.

These findings position Angiotensin III and related peptides as potent modulators of SARS-CoV-2 spike–AXL binding. The data suggest a potential link between RAAS dysregulation—common in cardiovascular disease and aging—and increased viral susceptibility or severity, mediated by altered peptide profiles (source: paper).

Comparison with Existing Internal Articles

Recent internal literature provides complementary perspectives on Angiotensin III’s mechanistic versatility:

• The article "Angiotensin III: Applied Workflows in RAAS and Viral Research" highlights Angiotensin III’s utility for dissecting AT1 and AT2 receptor signaling and its emerging role in viral pathogenesis. The new data from Oliveira et al. reinforce and mechanistically expand on this, showing that Angiotensin III not only acts as an aldosterone secretion inducer and pressor activity mediator, but also directly influences viral spike–host receptor interactions.
• "Angiotensin III (human, mouse): Advanced Insights for RAA..." discusses unique mechanisms and translational implications for Angiotensin III in cardiovascular and viral models, aligning with the reference study’s demonstration of cross-domain relevance.
• Additionally, "Angiotensin III (human, mouse): Atomic Insights for RAAS ..." and related resources emphasize the peptide’s validated role in modulating aldosterone and pressor effects, which may intersect with the altered RAAS peptide landscape during infection, as proposed by Oliveira et al. This suggests a broader context for experimentally leveraging Angiotensin III in infectious disease research.

Limitations and Transferability

Several caveats merit attention:

• The reported effects are based on in vitro binding assays using purified proteins and synthetic peptides. While these systems permit precise mechanistic dissection, they do not recapitulate the full complexity of in vivo peptide processing, receptor expression, or post-translational modifications (source: paper).
• Functional consequences in terms of actual viral entry, replication, or disease severity remain to be established. The study provides a molecular mechanism—enhanced spike–AXL engagement—but does not directly link this to infection outcomes.
• Peptide concentrations used in vitro may exceed physiological levels, and the tissue-specific expression of AXL versus ACE2 may modulate the relevance of these findings in different organs or disease states.

Protocol Parameters

• binding assay | 1–10 μM peptide | in vitro spike–receptor binding | enables detection of peptide-induced modulation | paper
• peptide sequence | Arg-Val-Tyr-Ile-His-Pro-Phe (Angiotensin III) | AT1/AT2, AXL binding studies | sequence requirements for activity mapping | paper
• solvent choice | water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), DMSO (≥93.1 mg/mL) | peptide stock preparation | supports broad assay compatibility | product_spec
• storage | -20°C, desiccated | long-term peptide stability | preserves peptide integrity for reproducible assays | product_spec
• recommended working range | 0.1–10 μM | cell-based or binding models | minimizes off-target effects, matches literature | workflow_recommendation

Why this cross-domain matters, maturity, and limitations

The demonstration that Angiotensin III and related peptides can enhance SARS-CoV-2 spike–AXL binding bridges cardiovascular and infectious disease research. This cross-domain insight is significant because RAAS peptide dysregulation is common in comorbidities associated with COVID-19 severity. However, the maturity of this bridge is at the mechanistic level; direct in vivo or clinical validation is pending. Therefore, researchers should interpret these findings as hypothesis-generating, guiding further studies into how peptide profiles may alter viral entry dynamics and pathogenesis (source: paper).

Research Support Resources

Researchers aiming to reproduce or extend this work can utilize Angiotensin III (human, mouse) (SKU A1043), a high-purity, validated cardiovascular research peptide suitable for in vitro and ex vivo binding assays and receptor signaling studies (source: product_spec). For detailed workflows on RAAS and viral interaction models, see the application-focused review at gap-27.com. Proper peptide solubility, handling, and storage protocols are essential to ensure experimental reproducibility and data integrity.